Blood pressure

Updated May 20, 2025.

🟢 CONTEC 08A-VET Veterinary/Animal Blood Pressure Monitor

CONTEC 08A-VET Veterinary/Animal Blood Pressure Monitor

Blood pressure

Monitoring

View on Amazon  💲 | Contec Health 

😺 Luna Says

Keeping tabs on blood pressure is super important for a CKD kitty like me! This device, plus regular vet visits, help make sure my blood pressure is just right.

🟢 CONTEC Neonate Cuff 6 to 11 cm

CONTEC Neonate Cuff 6 to 11 cm

Blood pressure

Monitoring

View on Contec Health 

🟢 Generic Atenolol Compounded Oral Oil Liquid

Generic Atenolol Compounded Oral Oil Liquid

Blood pressure

Drugs

Heart

View on Chewy 

References and resources
  1. “This study failed to identify an effect of subclinical HCM on owner assessed QOL or activity, or a treatment effect of atenolol on these variables at the dosage evaluated. These findings do not support a treatment benefit of atenolol for the goal of symptom reduction in cats with subclinical HCM.” — Coleman AE, DeFrancesco TC, Griffiths EH, Lascelles BDX, Kleisch DJ, Atkins CE, Keene BW. Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers. J Vet Cardiol. 2020 Aug;30:77-91. doi:10.1016/j.jvc.2020.06.002  (retrieved 2025-05-08)
  2. Drug Handout: Atenolol. CVCA. 2016. https://www.cvcavets.com/drug-handouts/atenolol/ 
  3. “If a cat is receiving beta-blockers (e.g., for previously diagnosed HCM with LVOTO), the dose should be carefully down-titrated or even stopped after a few weeks. This is because the intense neuroendocrine activation of CHF includes increased sympathetic drive to maintain cardiac output; beta-blockade may prevent some of this compensatory effort. However, the decision about discontinuing beta-blockers depends on each individual case (e.g., if there is significant LVOTO). Beta-blockers should never be started in a cat presenting with uncontrolled CHF; an interim analysis of heart failure treatments indicated significantly reduced survival in cats receiving this class of drug.” — Dukes-McEwan J, Partington C. Management of the cat with heart failure. Royal Canin Academy web site. 2022. https://academy.royalcanin.com/en/veterinary/management-of-the-cat-with-heart-failure  (retrieved 2025-05-08)
  4. “…at interim analysis, there was little evidence to suggest that chronic administration of furosemide plus either atenolol, dilacor, or enalapril at doses specified, provided any major advantage in clinical outcome versus administration of furosemide alone.” — Fox PR. Prospective, double-blinded, multicenter evaluation of chronic therapies for feline diastolic heart failure: interim analysis. Research Abstract Program of the 21st Annual ACVIM Forum Charlotte, NC, June 4-7, 2003. Journal of Veterinary Internal Medicine, 17: 398-399. doi:10.1111/j.1939-1676.2003.tb02465.x  (retrieved 2025-05-08)
  5. Jensen J, Henik RA, Brownfield M, Armstrong J. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Am J Vet Res. 1997 May;58(5):535-40. doi:10.2460/ajvr.1997.58.05.535 
  6. “Atenolol administration did not decrease NT-proBNP or cTnI concentrations in cats with severe left ventricular hypertrophy caused by hypertrophic cardiomyopathy. These results suggest that atenolol did not decrease myocardial ischemia and myocyte death in these cats.” — Jung, S.W. and Kittleson, M.D. (2011), The Effect of Atenolol on NT-proBNP and Troponin in Asymptomatic Cats with Severe Left Ventricular Hypertrophy because of Hypertrophic Cardiomyopathy: A Pilot Study. Journal of Veterinary Internal Medicine, 25: 1044-1049. doi:10.1111/j.1939-1676.2011.0754.x  (retrieved 2025-05-08)
  7. Macgregor JM, Rush JE, Rozanski EA, Boothe DM, Belmonte AA, Freeman LM. Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. Am J Vet Res. 2008 Jan;69(1):39-44. doi:10.2460/ajvr.69.1.39 
  8. Ogawa M, Kawamura A, Akabane R, Sakatani A, Miyakawa H, Hsu H-H, et al. Effects of ivabradine and atenolol on heart rate and heart rate variability in healthy cats over a 24 h period: a pilot study. Vet Rec Open. 2022; 9:e28. doi:10.1002/vro2.28 
  9. Quiñones M, Dyer DC, Ware WA, Mehvar R. Pharmacokinetics of atenolol in clinically normal cats. Am J Vet Res. 1996 Jul;57(7):1050-3. doi:10.2460/ajvr.1996.57.07.1050 
  10. Riesen, S.C., Schober, K.E., Cervenec, R.M. and Bonagura, J.D. (2011), Comparison of the Effects of Ivabradine and Atenolol on Heart Rate and Echocardiographic Variables of Left Heart Function in Healthy Cats. Journal of Veterinary Internal Medicine, 25: 469-476. doi:10.1111/j.1939-1676.2011.0705.x 
  11. “Our study failed to demonstrate an effect of atenolol on 5-year survival in cats with preclinical HCM.” — Schober KE, Zientek J, Li X, Fuentes VL, Bonagura JD. Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. J Vet Cardiol. 2013 Jun;15(2):93-104. doi:10.1016/j.jvc.2013.03.003  (retrieved 2025-05-08)
  12. Keisuke SUGIMOTO, Takuma AOKI, Yoko FUJII, Effects of atenolol on left atrial and left ventricular function in healthy cats and in cats with hypertrophic cardiomyopathy, Journal of Veterinary Medical Science, 2020, Volume 82, Issue 5, Pages 546-552. doi:10.1292/jvms.19-0670 
  13. Waterman M (2018). Pharmacodynamic evaluation of beta-blockade associated with atenolol in healthy dogs. Master’s Thesis, Virginia Polytechnic Institute and State University. http://hdl.handle.net/10919/97339 
  14. Wilkinson R. Do beta-blockers have a place in the treatment of feline hypertrophic cardiomyopathy (HCM)? 2021. https://www.vetpracticesupport.com/the-use-of-beta-blockers-in-feline-hypertrophic-cardiomyopathy-hcm/  (retrieved 2025-05-08)

🟢 Generic Telmisartan Compounded Oral Oil Liquid

Generic Telmisartan Compounded Oral Oil Liquid

Blood pressure

Drugs

Proteinuria

Renal

View on Chewy 

References and resources
  1. Committee for Medicinal Products for Veterinary Use. CVMP assessment report for Semintra to add new strength 10 mg/ml oral solution for cats to treat systemic hypertension. European Medicines Agency. 2018. https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6 
  2. Semintra (telmisartan oral solution) 10 mg/mL product insert. Boehringer Ingelheim Animal Health USA Inc. 2019. https://docs.boehringer-ingelheim.com/PI/Theras/Semintra_PI.pdf 
  3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. doi:10.1056/NEJMoa011161 
  4. Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33: 478-488. doi:10.1111/jvim.15429 
  5. Coleman A, Elliott J. Inhibition of the renin-angiotensin-aldosterone system in cats and dogs: The emerging role of angiotensin II receptor blockers. International Renal Interest Society (IRIS). 2022. http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html 
  6. Girens R, Swift S. Telmisartan for Treating Systemic Hypertension. Today’s Veterinary Practice. 2019. https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/ 
  7. Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413-422. doi:10.1111/jvim.15394 
  8. Gordon SG, Saunders AB, Malcolm E. Angiotensin II Receptor Antagonists for Use in Animals. Merck Veterinary Manual. 2023. https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals 
  9. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi:10.1681/ASN.2005050522 
  10. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. doi:10.2174/1381612811319170009 
  11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. doi:10.1056/NEJMoa011303 
  12. Sent, U., Gössl, R., Elliott, J., Syme, H.M. and Zimmering, T. (2015), Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med, 29: 1479-1487. doi:10.1111/jvim.13639 
  13. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. doi:10.1001/jama.288.19.2421 
  14. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs. 2020 Jun;80(8):797-811. doi:10.1007/s40265-020-01290-3 

🟢 Vmed Technology vet-dop2

Vmed Technology vet-dop2

Veterinary Doppler blood pressure system.

Blood pressure

Monitoring

manufacturer page 

View on Vmed Technology 

Blood pressure references and resources

  1. Committee for Medicinal Products for Veterinary Use. CVMP assessment report for Semintra to add new strength 10 mg/ml oral solution for cats to treat systemic hypertension. European Medicines Agency. 2018. https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6 
  2. Hypertension, chronic kidney disease and the renin-angiotensin-aldosterone system (2020). American Animal Hospital Association. https://www.aaha.org/wp-content/uploads/globalassets/05-pet-health-resources/critical-connections_web.pdf 
  3. Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018; 32: 1803–1822. doi:10.1111/jvim.15331 
  4. Adin D, Atkins C, Domenig O, Glahn C, DeFrancesco T, Meurs K. Evaluation of Renin-Angiotensin-Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine. Animals (Basel). 2023 Nov 10;13(22):3479. doi:10.3390/ani13223479 
  5. Brown SA, Brown CA, Jacobs G, Stiles J, Hendi RS, Wilson S. Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. Am J Vet Res. 2001 Mar;62(3):375-83. doi:10.2460/ajvr.2001.62.375 
  6. Carter J. Hypertensive ocular disease in cats: A guide to fundic lesions to facilitate early diagnosis. Journal of Feline Medicine and Surgery. 2019;21(1):35-45. doi:10.1177/1098612X18818668 
  7. Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33: 478-488. doi:10.1111/jvim.15429 
  8. Coleman A, Elliott J. Inhibition of the renin-angiotensin-aldosterone system in cats and dogs: The emerging role of angiotensin II receptor blockers. International Renal Interest Society (IRIS). 2022. http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html 
  9. Garcia Marrero TM, Ward JL, Tropf MA, Bourgois-Mochel A, Guillot E, Domenig O, Yuan L, Kundu D, Mochel JP. Effect of amlodipine on the circulating renin-angiotensin-aldosterone system in healthy cats. J Vet Intern Med. 2024 Mar-Apr;38(2):913-921. doi:10.1111/jvim.17006 
  10. Girens R, Swift S. Telmisartan for Treating Systemic Hypertension. Today’s Veterinary Practice. 2019. https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/ 
  11. Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413-422. doi:10.1111/jvim.15394 
  12. Gordon SG, Saunders AB, Malcolm E. Angiotensin II Receptor Antagonists for Use in Animals. Merck Veterinary Manual. 2023. https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals 
  13. Hampton A, Ford A, Cox RE 3rd, Liu CC, Koh R. Effects of music on behavior and physiological stress response of domestic cats in a veterinary clinic. J Feline Med Surg. 2020 Feb;22(2):122-128. doi:10.1177/1098612X19828131 
  14. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi:10.1681/ASN.2005050522 
  15. Jepson, R.E., Syme, H.M. and Elliott, J. (2014), Plasma Renin Activity and Aldosterone Concentrations in Hypertensive Cats with and without Azotemia and in Response to Treatment with Amlodipine Besylate. J Vet Intern Med, 28: 144-153. doi:10.1111/jvim.12240 
  16. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. doi:10.2174/1381612811319170009 
  17. Kothari N, Ganguly B (2014). Potential Drug-Drug Interactions among Medications Prescribed to Hypertensive Patients. J Clin of Diagn Res. 8(11), HC01-HC04. doi:10.7860/JCDR/2014/10032.5091 
  18. Lalor SM, Connolly DJ, Elliott J, Syme HM. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J Vet Cardiol. 2009 May;11 Suppl 1:S71-9. doi:10.1016/j.jvc.2009.01.004 
  19. Lawson JS, Jepson RE. Feline comorbidities: The intermingled relationship between chronic kidney disease and hypertension. Journal of Feline Medicine and Surgery. 2021;23(9):812-822. doi:10.1177/1098612X211037872 
  20. Linek J. Iris aneurysm in feline hypertensive oculopathy. Vet Ophthalmol. 2020; 23: 436-441. doi:10.1111/vop.12738 
  21. Maggio F, DeFrancesco TC, Atkins CE, Pizzirani S, Gilger BC, Davidson MG. Ocular lesions associated with systemic hypertension in cats: 69 cases (1985-1998). J Am Vet Med Assoc. 2000 Sep 1;217(5):695-702. doi:10.2460/javma.2000.217.695 
  22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 Jun;25(6):1105-87. doi:10.1097/HJH.0b013e3281fc975a 
  23. Mika MISHINA, Nobuyoshi WATANABE, Toshifumi WATANABE, Diurnal Variations of Blood Pressure in Cats, Journal of Veterinary Medical Science, 2006, Volume 68, Issue 3, Pages 243-248. doi:10.1292/jvms.68.243 
  24. Quimby JM. Maropitant Use in Cats. Today’s Veterinary Practice. 2020. https://todaysveterinarypractice.com/pharmacology/maropitant-use-in-cats/ 
  25. Quimby JM, Jones SE, Saffire A, et al. Assessment of the effect of gabapentin on blood pressure in cats with and without chronic kidney disease. Journal of Feline Medicine and Surgery. 2024;26(5). doi:10.1177/1098612X241240326 
  26. Scansen BA. Which Drugs Can Control Systemic Arterial Hypertension in Dogs & Cats. Plumb’s Therapeutics Brief. May 2016. https://assets.ctfassets.net/4dmg3l1sxd6g/j7ipcDz6lLAmgrZV2uarX/0d81ffc57d077ea4a8ad40716bc584a3/rx-solutions_which-drugs-can-control-systemic-arterial-hypertension-in-dogs–cats-28111-article.pdf 
  27. Sent, U., Gössl, R., Elliott, J., Syme, H.M. and Zimmering, T. (2015), Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med, 29: 1479-1487. doi:10.1111/jvim.13639 
  28. Taylor SS, Sparkes AH, Briscoe K, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats. Journal of Feline Medicine and Surgery. 2017;19(3):288-303. doi:10.1177/1098612X17693500 
  29. Thompson J. Management of hypertension in a geriatric cat. Can Vet J. 2004 May;45(5):427-9. https://pmc.ncbi.nlm.nih.gov/articles/PMC548629/ 
  30. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. doi:10.1001/jama.288.19.2421 
  31. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs. 2020 Jun;80(8):797-811. doi:10.1007/s40265-020-01290-3 

👉 Product links on this page marked with a 💲 may earn the site a modest commission.

Something missing? Questions, comments, or corrections? Email chuck -at- weathermuffin.com

Disclaimers: While I have strived to include only products which I have used or would use with my own CKD kitty, appearance here should not be construed as endorsement. Every kitty and every kitty's situation is unique. This web site's operator is not responsible for your cat's well-being; you alone are. Do not start, stop, or adjust any medications or supplements without consulting with your veterinarian.

© 2024-2025 Weathermuffin, LLC